How MS Treatment May Change Virus Defense and Nerve Health
By MS Buddy ·
Summarized from Journal of neurology, Oct 2026 · PubMed. AI-generated summary. Not medical advice.
Research by Silvia D'Orso, Giovanna Borsellino and 17 colleagues at LIFE Institute for Research and Health Care-Santa Lucia IRCCS, San Camillo-Forlanini Hospital and 2 other institutions in Italy and the United Kingdom.
Key Takeaway
In a small study, people taking the MS treatment ocrelizumab had a lower immune response to one virus, while their responses to two other viruses were similar to those of other groups.
What They Found
Researchers compared blood samples from adults with relapsing MS who were untreated or taking ocrelizumab, a medicine that removes certain immune cells called B cells. As expected, people taking the medicine had far fewer of these B cells, but the treatment was also linked to changes in other immune cells. Their helper T cells, which help direct the body's defenses, showed a lower response to Epstein-Barr virus than those of untreated people with MS. Responses to two other viruses, CMV and the virus that causes COVID-19, were similar across the groups. In untreated people with MS, higher levels of one inflammation-related blood signal went along with higher levels of a protein that can rise when nerve fibers are injured.
Who Should Care and Why
People taking ocrelizumab may find this study useful because it shows that the medicine affects more than the B cells it is designed to remove. A lower response to Epstein-Barr virus in a blood test does not mean a person will get sick from that virus, but it gives researchers a question to study further. People with MS and caregivers can ask their care team how treatment affects immune health and which routine precautions or vaccines are recommended for them. The possible link between an inflammation signal and nerve injury may interest clinicians looking for better ways to track MS, much like using warning lights on a dashboard. For now, the findings do not call for a change to anyone's treatment or daily routine.
Important Considerations
This study took blood samples at one point in time, so it cannot show that ocrelizumab caused every difference or that the inflammation signal caused nerve injury. The groups were small, and everyone taking an anti-CD20 treatment received ocrelizumab, so the results may not apply to every person or medicine. Blood tests cannot tell us from this study whether someone is more likely to get an infection or how their MS will change over time.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Journal of neurology by et al.. Reproduced from the PubMed record.
CD20-targeting monoclonal antibodies are highly effective therapies for relapsing multiple sclerosis (MS). We examined how anti-CD20 therapy reshapes antiviral T-cell immunity, innate inflammatory tone, and blood markers of neuroaxonal injury. In this cross-sectional study, adults with relapsing MS were enrolled at two neurological centers in Rome. An immunophenotyping cohort (45 untreated, 25 anti-CD20-treated, all receiving ocrelizumab) was profiled by high-parameter flow cytometry across more than 40 immune populations. A separate antiviral cohort (24 untreated, 13 treated, 19 healthy donors) was assessed for T-cell responses to Epstein-Barr virus (EBV), cytomegalovirus (CMV) and SARS-CoV-2 by activation-induced marker assay, for cytokine and chemokine release by multiplex assay, and for serum neurofilament light chain (sNfL) by single-molecule array. Groups were compared by Kruskal-Wallis with Dunn's correction; correlations used Spearman's rank test. Anti-CD20 therapy depleted total and switched-memory B cells while sparing antibody-secreting cells and reduced absolute counts of follicular helper T cells and mucosal-associated invariant T cells. Untreated patients with MS (pwMS) showed elevated monocyte interleukin-1β and monocyte chemotactic protein-3 (MCP-3) and impaired pDC cell interferon-α production, whereas pDC IFN-α responses in ocrelizumab-treated pwMS were comparable to those in HD. EBV-specific CD4+ T-cell counts and stimulation index were selectively lower ocrelizumab-treated pwMS, whereas CMV- and SARS-CoV-2-specific responses were comparable across groups. sNfL was elevated in untreated pwMS and correlated with MCP-3 at baseline and after EBV stimulation. Anti-CD20 therapy acts on immune circuits beyond B cells, selectively contracting EBV-directed helper T-cell immunity while sparing other antiviral responses, and identifies MCP-3 as a candidate blood marker associated with neuroaxonal injury in pwMS.
Trials you could look into
This study looked at a treatment with MS trials currently recruiting or under way.
Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.
Explore more research
Check out the MS Buddy app
It’s free, with no ads. Built by people living with MS.
Related MS research
11/8/2026
A study finds a short survey may help spot worry about the unknown in people with MS. Learn what it
Read More
11/9/2026
A U.S. study found anxiety, depression, and pain more often in MS hospital stays. Learn why asking f
Read More
11/7/2026
A study of 360 people with MS links past suicide attempts with depression, smoking, and childhood ha
Read More
11/6/2026
A study of children with MS linked higher propionate, a substance made in the gut, with less disease
Read More
11/4/2026
Could a short voice recording help track MS changes? Learn why speech-checking tools show promise fo
Read More
11/4/2026
A four-year MS study links the condition of nerve coating in brain lesions with later thinking speed
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.